Australia Health

Monash IVF Group (ASX:MVF) reported FY26 revenue of $269.5 million alongside an underlying net profit after tax of $16.1 million.

Austco Healthcare (ASX:AHC) recorded a 15.8% revenue increase in FY26 to reach a record $94.2 million.

Respiratory imaging business 4DMedical (ASX:4DX) reported a 77% increase in annual scan volume to 344,075 scans for FY26.

LTR Pharma (ASX:LTP) reported $19.7 million in cash with no dent for the year ended June 30.

Clinuvel Pharmaceuticals (ASX:CUV) announced its board is considering changing its holding structure to list on the Nasdaq and delist from the ASX.

Sigma Healthcare (ASX:SIG) reported full-year revenue of $10.8 billion and normalised EBIT of $1.09 billion for the period ended June 30.

Ramsay Health Care (ASX:RHC) reported a full-year net profit after tax of $329.2 million for the twelve months ended June 30.

Neuren Pharmaceuticals (ASX:NEU) declared a fully franked interim dividend of 15 cents per share for H1 2026.

PolyNovo (ASX:PNV) generated total revenue of $150 million for the year ended June 30, marking a 16.1% increase.

Neuren Pharmaceuticals (ASX:NEU) secured European Commission marketing authorisation for DAYBU (trofinetide).

Nanosonics (ASX:NAN) increased its annual revenue by 3% to $203.9 million for the financial year ended June 30.

Integral Diagnostics (ASX:IDX) announced its financial results for the year ended June 30, delivering an operating net profit after tax of $47.4 million.